BioStock Investor Meeting: Interview with Elicera Therapeutics
Elicera Therapeutics, led by CEO Jamal El-Mosleh, is developing immuno-oncology drug candidates based primarily on oncolytic viruses and CAR T-cells. The product portfolio includes four drug candidates and the company has also developed the technology platform iTANK. BioStock interviewed El-Mosleh about Elicera’s work at the BioStock Investor Meeting in Stockholm.
Watch the interview with Elicera Therapeutics’ CEO Jamal El-Mosleh below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
